source
- BioNTech trims full-year COVID-19 vaccine sales outlook by up to 20% amid weak demandBioNTech announced it is lowering its full-year sales guidance for its COVID-19 vaccine. The company cut the midpoint of its outlook by almost 20%, moving the range to €1.6-1.9 billion from the pr…
- Pathos AI acquires bispecific ADC from Alphamab and secures AstraZeneca partnershipPathos AI announced it will pay $125 million upfront for the rights to JSKN016, a bispecific TROP2/HER3 antibody‑drug conjugate from China’s Alphamab Oncology. The agreement also includes up to $2.…